Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Lannett Plans Seven Launches In Fiscal Year 2021
As Its Respiratory And Biosimilar Candidates ‘Remain On Track’
Sep 19 2025
•
By
Akriti Seth
Lannett reports a stable first quarter of fiscal 2020, with a minor drop in sales • Source: Shutterstock
More from Biosimilars
More from Products
